BALPHARMA NSE filing

Compliance certificate for Structured Digital Database for quarter ended 30 Sep 2025

The RealCase readLow impact Neutral

Bal Pharma Limited confirms the existence of a Structured Digital Database (SDD) for the quarter ended September 30, 2025, ensuring compliance with SEBI regulations.

Why it matters

This is a standard compliance disclosure and is unlikely to have a significant impact on the company's stock price or operations.

The market read

The announcement is a routine compliance update and does not contain any information that would be considered positive or negative.

* Bal Pharma Limited confirms the existence of a Structured Digital Database (SDD). * Control measures are in place to manage access to the SDD. * All Unpublished Price Sensitive Information (UPSI) disseminated in the previous quarter has been captured in the database. * The system has captured the nature of UPSI along with the date and time. * The database is maintained internally with an audit trail. * The database is non-tamperable and can maintain records for 8 years. * The company captured 01 event during the quarter ended 30.09.2025.

Filing to action

What to do with a filing like this

Bal Pharma Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.

That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.

See the model portfolios
Primary source

A plain-language summary of a public exchange filing by Bal Pharma Limited. Read the original for the full detail.

View original filing